First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1186/s13045-016-0254-5
Published Online: 2016-03-10
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Li, Tianhong
LoRusso, Patricia
Maitland, Michael L.
Ou, Sai-Hong Ignatius
Bahceci, Erkut
Ball, Howard A.
Park, Jung Wook
Yuen, Geoffrey
Tolcher, Anthony